Form 4: BIO-TECHNE CFO Reports RSU Vesting and Tax-Related Stock Sale

Sentiment:

Insider Transaction Report 5 November 2025 4:46 PM

BIO-TECHNE's CFO, James Hippel, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

James Hippel, CFO of BIO-TECHNE Corp, reported transactions involving the company's common stock.
On November 3, 2025, Hippel acquired 13,159 shares of common stock at a price of $0, resulting from the vesting of restricted stock units.
On the same date, he acquired an additional 11,545 shares of common stock at a price of $0, also due to the vesting of restricted stock units.
Following these acquisitions, Hippel's direct beneficial ownership of common stock was 154,587 shares.
Also on November 3, 2025, Hippel disposed of 11,865 shares of common stock at a price of $62.57. This disposition was likely to cover tax liabilities associated with the RSU vesting.
After all reported transactions, Hippel's direct beneficial ownership of common stock stands at 142,722 shares.
The filing also details various outstanding stock options and performance restricted stock units with different vesting schedules extending through August 2035.

Sentiment

Score: 5

Explanation: This is a routine Form 4 filing reporting executive compensation transactions (RSU vesting and tax-related share disposition). It provides no new information regarding company performance, strategy, or financial health, thus having a neutral impact on sentiment.

Positives

The vesting of restricted stock units indicates the achievement of employment milestones or performance goals, reflecting continued tenure and potentially successful performance by the CFO.
The acquisition of shares at $0 cost increases the CFO's direct equity stake in the company, aligning his interests with shareholders.

Negatives

The disposition of 11,865 shares, even if for tax purposes, reduces the CFO's direct ownership stake in the company.

Future Outlook

The filing details future vesting schedules for various stock options and restricted stock units, indicating a long-term incentive structure for the CFO extending through August 2035. Performance-based units are contingent on achieving certain goals.

Industry Context

This Form 4 filing is a routine disclosure of executive stock transactions, common across all publicly traded companies. It reflects standard executive compensation practices, including equity awards and tax-related dispositions, which are prevalent in the biotechnology and life sciences industry where BIO-TECHNE operates.

Comparison to Industry Standards

The use of Restricted Stock Units (RSUs) and stock options as a significant component of executive compensation is a standard practice across industries, including the biotechnology sector, aligning executive incentives with shareholder value creation.
The "sell to cover" transaction (Code F) for tax withholding upon RSU vesting is a common and expected practice for executives receiving equity compensation, ensuring compliance with tax obligations without requiring personal cash outlays.
The long-term vesting schedules for stock options and performance-based RSUs, extending over several years, are consistent with best practices in corporate governance to promote long-term strategic focus and retention of key executives.

Related Party Transactions

The transactions reported are between the company and its CFO, which are considered related party transactions in the context of executive compensation. These are standard and disclosed as required.

Stakeholder Impact

Shareholders: The transactions represent a routine part of executive compensation. The CFO's continued equity ownership aligns his interests with shareholders. The disposition of shares for tax purposes is a common practice and not indicative of a lack of confidence.
Employees: The compensation structure for the CFO, involving equity awards, may reflect the broader compensation philosophy within the company for key personnel.

Next Steps

Future vesting of stock options and restricted stock units will occur on various dates as detailed in the filing, contingent on continued employment and, for performance units, achievement of specific goals.

Key Dates

Date	Description
08/15/2023	First vesting date for a tranche of 11,305 stock options with an exercise price of $94.52.
08/15/2024	Vesting date for a tranche of 11,305 stock options with an exercise price of $94.52; also a vesting date for 11,481 stock options with an exercise price of $84.61.
08/15/2025	Vesting date for a tranche of 11,305 stock options with an exercise price of $94.52; vesting date for 4,010 restricted stock units; vesting date for 11,481 stock options with an exercise price of $84.61; vesting date for 8,104 stock options with an exercise price of $74.91.
11/01/2025	Vesting date for 13,159 restricted stock units and 11,545 restricted stock units.
11/03/2025	Transaction date for RSU vesting and common stock disposition.
11/05/2025	Signature date of the reporting person's attorney-in-fact.
08/07/2026	Expiration date for stock options with an exercise price of $47.6.
08/15/2026	Vesting date for a tranche of 11,305 stock options with an exercise price of $94.52; vesting date for performance restricted stock units if goals are achieved; vesting date for 11,480 stock options with an exercise price of $84.61; vesting date for 4,010 restricted stock units; vesting date for 8,104 stock options with an exercise price of $74.91; vesting date for 4,903 restricted stock units; vesting date for 12,544 stock options with an exercise price of $53.6.
11/01/2026	Vesting date for 11,545 restricted stock units.
08/05/2027	Expiration date for stock options with an exercise price of $66.97.
08/15/2027	Vesting date for 11,481 stock options with an exercise price of $84.61; vesting date for performance restricted stock units if goals are achieved; vesting date for 4,011 restricted stock units; vesting date for 8,104 stock options with an exercise price of $74.91; vesting date for 4,903 restricted stock units; vesting date for 12,544 stock options with an exercise price of $53.6.
11/01/2027	Vesting date for 11,544 restricted stock units.
08/06/2028	Expiration date for stock options with an exercise price of $120.46.
08/15/2028	Vesting date for 8,105 stock options with an exercise price of $74.91; vesting date for performance restricted stock units if goals are achieved; vesting date for 4,904 restricted stock units; vesting date for 12,544 stock options with an exercise price of $53.6.
08/15/2029	Expiration date for stock options with an exercise price of $94.52.
08/15/2030	Expiration date for performance stock options with an exercise price of $84.61; expiration date for stock options with an exercise price of $84.61.
08/15/2034	Expiration date for stock options with an exercise price of $74.91.
08/15/2035	Expiration date for stock options with an exercise price of $53.6.

Recommendation

hold

This Form 4 filing is a routine disclosure of executive compensation transactions (vesting of restricted stock units and a tax-related sale of shares). It does not contain any new information regarding the company's operational performance, strategic direction, or financial outlook that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, maintaining the current investment stance based on broader company fundamentals and market conditions, which are not addressed in this specific filing.

Keywords

BIO-TECHNE Corp, TECH, Form 4, Insider Trading, CFO, James Hippel, Restricted Stock Units, RSU Vesting, Stock Options, Executive Compensation, Share Disposition, Tax Withholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.